Effect and risk factor of adverse drug events in using dapaglilfozin with type 2 diabetes mellitus patients.

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-HPS-068
• By: KIM, Kwi (Seoul National University Hospital, Pharmacy, Seoul, Korea, Republic Of)
• Co-author(s): Kwi Suk Kim: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
  Hyung Woo Lee: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
  Sun Joon Moon: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
  Hee Sim Han: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
  Eun Jeong Shin: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
  Jin Hee Baek: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
  Yoon Sook Cho: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
  Young Min Cho: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
  
• Abstract:

  Background

  US">Dapagliflozin, a selective sodium-glucose co-transporter 2(SGLT2) inhibitor, lowers blood glucose by reducing glucose reabsorption at the proximal renal tubule in an insulin-independent manner.

  Purpose

  US">We aimed to evaluate the efficacy and safety of dapagliflozin and to identify the risk factors of adverse drug events in patients..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login